Publicacións (88) Publicacións de José Luis Díaz Díaz

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  3. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet, Vol. 403, Núm. 10421, pp. 55-66

  4. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Control de la hipercolesterolemia en España: una misma situación con diferentes realidades autonómicas

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 5, pp. 219-225

  3. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet

  4. Impact of conducting a genetic study on the management of familial hypercholesterolemia; A retrospective cohort study of 4854 patients from the SEA Dyslipidemia Registry

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 717-731

  5. Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain

    Atherosclerosis, Vol. 375, pp. 38-44

  6. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  7. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

  8. Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia: Estudio GALIPEMIAS

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 178-184

  9. Recomendaciones nutricionales en la prevención y tratamiento de la dislipemia aterogénica: Grupo de Trabajo Dislipemia Aterogénica, Sociedad Española de Arteriosclerosis

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 3, pp. 155-163

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study

    Medicina Clinica, Vol. 158, Núm. 11, pp. 531-539

  3. Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 253-260

  4. Estándares SEA 2022 para el control global del riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

  5. Extended anticoagulation for venous thromboembolism: A survey of the American Venous Forum and the European Venous Forum

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 10, Núm. 5, pp. 1012-1020.e3

  6. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?

    Current Atherosclerosis Reports, Vol. 24, Núm. 6, pp. 427-434

  7. Nutritional recommendations in the prevention and treatment of atherogenic dyslipidemia

    Clinica e Investigacion en Arteriosclerosis